Filing Details

Accession Number:
0000905148-24-001355
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-05-10 17:06:15
Reporting Period:
2024-05-08
Accepted Time:
2024-05-10 17:06:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1439725 Biodesix Inc BDSX Services-Medical Laboratories (8071) 203986492
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1980594 Chris Vazquez 919 West Dillon Rd
Louisville CO 80027
Chief Accounting Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-05-08 601 $0.00 10,159 No 4 M Direct
Common Stock Disposition 2024-05-09 244 $1.48 9,915 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2024-05-08 601 $0.00 601 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
4,212 No 4 M Direct
Footnotes
  1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
  2. Includes an aggregate 10 shares that were inadvertently reported as being sold on February 9 and February 12, 2024 in the Form 4 filed by the Reporting Person on February 12, 2024.
  3. These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
  4. The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.43 to $1.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.